Skip to main
EYPT
EYPT logo

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EyePoint Pharmaceuticals (EYPT) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 50%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

EyePoint Pharmaceuticals Inc. has experienced a significant increase in research and development (R&D) expenses, rising to $132.9 million from $64.7 million a year ago, indicating strong commitment and investment in advancing its product pipeline. The company also reported promising clinical results for its lead product DURAVYU, which demonstrated significant improvements in visual acuity and anatomical control in treated patients, reinforcing the potential efficacy of its therapies. Despite a modest increase in net product revenue quarter-over-quarter, the positive data from ongoing trials, coupled with the company's innovative treatment methods targeting various eye diseases, supports a favorable outlook for its continued growth in the ophthalmic market.

Bears say

EyePoint Pharmaceuticals has experienced a decline in the efficacy of its high-dose Duravyu treatment for the improvement of best-corrected visual acuity (BCVA), with a final change of 7.1 ETDRS letters compared to 7.3 letters for the control cohort after 24 weeks. The company's management acknowledged this drop-off as potentially influenced by an outlier patient case, which raises concerns about the overall reliability and consistency of the treatment's performance. Furthermore, there is an implication that current projections could face downward revisions, adversely affecting the company’s financial outlook and valuation metrics.

EyePoint Pharmaceuticals (EYPT) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 50% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About EyePoint Pharmaceuticals (EYPT) Forecast

Analysts have given EyePoint Pharmaceuticals (EYPT) a Buy based on their latest research and market trends.

According to 14 analysts, EyePoint Pharmaceuticals (EYPT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

EyePoint Pharmaceuticals (EYPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.